

University of Groningen

Antidepressant use during pregnancy

Ramsteijn, Anouschka

DOI:
[10.33612/diss.133209609](https://doi.org/10.33612/diss.133209609)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Ramsteijn, A. (2020). *Antidepressant use during pregnancy: Exploring novel (neuro)biological effects in rat mothers and offspring*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.
<https://doi.org/10.33612/diss.133209609>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Chapter 4

Antidepressant treatment with fluoxetine during pregnancy and lactation modulates the gut microbiome and metabolome in a rat model relevant to depression

Anouschka S. Ramsteijn^{1,2,3}

Eldin Jašarević^{2,3,4}

Danielle J. Houwing¹

Tracy L. Bale^{2,3,4}

Jocelien D.A. Olivier¹

¹Department of Neurobiology, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, NL

²Center for Host-Microbial Interactions, ³Department of Biomedical Sciences, School of Veterinary Medicine and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. ⁴Department of Pharmacology, Center for Epigenetic Research in Child Health and Brain Development, University of Maryland School of Medicine, Baltimore MD 21201, USA

Abstract

Up to 10% of women use selective serotonin reuptake inhibitor (SSRI) antidepressants during pregnancy and postpartum. Recent evidence suggests that SSRIs are capable of altering the gut microbiota. However, the interaction between maternal depression and SSRI use on bacterial community composition and the availability of microbiota-derived metabolites during pregnancy and lactation is not clear. We studied this using a rat model relevant to depression, where adult females with a genetic vulnerability and stressed as pups show depressive-like behaviors. Throughout pregnancy and lactation, females received the SSRI fluoxetine or vehicle. High-resolution 16S ribosomal RNA marker gene sequencing and targeted metabolomic analysis were used to assess the fecal microbiome and metabolite availability, respectively. Not surprisingly, we found that pregnancy and lactation segregate in terms of fecal microbiome diversity and composition, accompanied by changes in metabolite availability. However, we also showed that fluoxetine treatment altered important features of this transition from pregnancy to lactation most clearly in previously stressed dams, with lower fecal amino acid concentrations. Amino acid concentrations, in turn, correlated negatively with the relative abundance of bacterial taxa such as *Prevotella* and *Bacteroides*. Our study demonstrates an important relationship between antidepressant use during the perinatal period and maternal fecal metabolite availability in a rat model relevant to depression, possibly through parallel changes in the gut microbiome. Since microbial metabolites contribute to homeostasis and development, insults to the maternal microbiome by SSRIs might have health consequences for mother and offspring.

Introduction

Dysregulation of the neurotransmitter serotonin (also referred to as 5-hydroxytryptamine or 5-HT) in the brain is a widely recognized hallmark of major depressive disorder.¹ Selective serotonin reuptake inhibitor (SSRI) antidepressants target the serotonin transporter (SERT), thereby influencing the serotonergic tone.² Serotonin and SERT are particularly well-known for playing crucial regulatory roles in the brain, but they also act in many peripheral tissues.³ Nearly 95% of the body's serotonin resides within the gastrointestinal tract, where it is mainly produced by enterochromaffin cells.⁴ Interestingly, germ-free and antibiotic-treated mice show lower levels of colonic and serum serotonin. This is reversible by microbial colonization, suggesting an important role for members of the gut microbiome in modulating serotonin availability.⁵ Indeed, the gut microbiota synthesizes tryptophan, the precursor of serotonin, and promotes serotonin biosynthesis in the host organism.⁵ Conversely, host serotonin signaling impacts the gut microbiota composition as we have shown in rats,⁶ and others in mice,⁷ with reduced or no SERT gene expression. Correspondingly, *in vitro* studies have shown that serotonin affects the growth of microbes such as *Escherichia coli* and *Rhodospirillum rubrum*,⁸ and activates bacterial quorum sensing.⁹ Several studies have found alterations in the gut microbiota composition of patients with major depression,^{10–16} and rodents with depressive-like symptoms.^{17–21} Moreover, recent human population-based studies,^{16,22,23} as well as rodent experiments,^{24–29} showed that SSRIs modulate the

gut microbiota composition, an effect that may be related to their *in vitro* antimicrobial properties.^{24,30,31}

The gut microbiota synthesizes a variety of metabolites that reach the systemic circulation,^{32,33} which is of special relevance during pregnancy and lactation when there is a high metabolic demand.³⁴ Indeed, pregnancy is characterized by hormonal, immunological and metabolic changes, paralleled by remodeling of the maternal gut microbiome.³⁵ Environmental and pharmacological insults disrupt the compositional and functional states of the maternal gut microbiota, as demonstrated by several animal studies focusing on stress,³⁶ diet,³⁷ and antibiotic use during pregnancy.³⁸ Despite clear evidence that the microbiome interacts with serotonin homeostasis,³⁹ it is currently unknown how alterations in serotonin signaling affect the maternal gut microbiome during the perinatal period. An estimated 7 to 13% of women suffer from a major depressive disorder in the perinatal period.⁴⁰ It was recently shown that there are associations between anxiety and the fecal microbial composition during pregnancy.⁴¹ Between 1 and 10% of pregnant women take SSRI antidepressants,⁴⁰ further highlighting the relevance of a potential effect of SSRI medication during this period on the gut microbiota and its metabolic output.

We investigated the hypothesis that a depressive-like phenotype, SSRI antidepressant treatment, and their combination affect the microbial community composition and function during pregnancy and the postpartum period. To this end, we used a genetic rat model of maternal vulnerability (MV) in combination with early life stress (sMV) or control handling (cMV). In adulthood, sMV females show a depressive-like phenotype, reflected in a lower sucrose preference and lower neural growth factor gene expression than cMV females.⁴² We treated sMV and cMV rats dams daily with fluoxetine (FLX), a commonly used SSRI, or vehicle (Veh) throughout pregnancy and lactation. Weekly fecal samples were collected for 16S rRNA gene sequencing. In addition, targeted metabolomic analysis of amino acids, short-chain fatty acids and bile acids was done on a subset of samples. We examined the hypothesis that depressive-like symptoms and antidepressant treatment during pregnancy and lactation affect the maternal fecal microbiome and its functional capacity. We expected the combination of sMV and FLX to have the strongest effect.

Materials and methods

Experimental animals

The animals came from our colony of serotonin transporter knockout ($SERT^{-/-}$, $Slc6a41^{Huber}$) Wistar rats at the University of Groningen (Groningen, the Netherlands), and were derived from outcrossing $SERT^{+/-}$ rats.⁷⁴ Animals were supplied *ad libitum* with standard lab chow (RMH-B, AB Diets; Woerden, the Netherlands) and water and were kept on a 12:12 h light-dark cycle (lights off at 11:00 h), with an ambient temperature of 21 ± 2 °C and humidity of 50 ± 5 %. Cages were cleaned weekly, and animals were provided with a wooden stick for gnawing (10x2x2cm) and nesting material (Enviro-dri™, Shepherd Specialty Papers, Richland, MI, USA). During pregnancy, females were housed individually in type III Makrolon cages (38.2x22.0x15.0cm) and stayed with their pups until postnatal day (PND)21. Animals were weaned at PND21 and group housed in same-sex cages

of 3-5 animals in type IV (55.6x33.4x19.5cm) Makrolon cages. Genotyping of the animals was performed as described previously.⁶ All experimental procedures were approved by the Institutional Animal Care and Use Committee of The University of Groningen and were conducted in agreement with the Law on Animal Experiments of The Netherlands.

Early life stress in a rat model of maternal vulnerability

Our rat model of maternal vulnerability (MV) consists of heterozygous SERT knockout ($SERT^{+/-}$) female rats. The early life stress protocol was conducted as previously described.⁶ In short, $SERT^{+/-}$ females were mated with $SERT^{+/-}$ males (F0). Females were left undisturbed until delivery, which was defined as PND0. From PND2 to PND15, pups were either separated from the dam for 6 hours per day – early life stress, or handled 15 minutes per day to control for litter disturbances – control handling (Figure 1a). Randomization was performed by alternating assignment of stress or control condition to litters placed in the same room. Both groups were handled by the same experimenters. The $SERT^{+/-}$ female pups from these nests (F1) then matured to become the sMV- and cMV females.

Breeding and fluoxetine treatment

sMV and cMV females were mated with wildtype males. Females were between the age of 3 and 6 months, and mated when in estrus (checked with a disinfected impedance meter, model MK-11, Muromachi, Tokyo, Japan). This was termed gestational day (GD)0. The males were removed after 24 hours, and the females stayed isolated in a type III cage. Throughout pregnancy and lactation, from GD1 until PND21, the dams were weighed and received an oral gavage of either a clinically relevant dose of 10 mg/kg fluoxetine (FLX, Fluoxetine 20 PCH, Pharmachemie BV, the Netherlands),⁷⁵ or vehicle (Veh) daily at 11:00AM (Figure 1b). Methylcellulose (Sigma Aldrich Chemie BV, Zwijndrecht, the Netherlands) was used for Veh injections since it is the constituent of the fluoxetine capsule. FLX (5 mg/mL) and MC (1%) solutions were prepared with autoclaved water. The gavage volume ranged from 0.9 mL to 2.0 mL (depending on body weight). Animals were treated orally by gently picking up the animal without restraint, and using flexible PVC feeding tubes (40 cm length, Vygon, Valkenswaard, the Netherlands) in order to minimize discomfort and stress in the animals. It should be noted that our lab has been confronted with thus far unexplained mortality in about one fourth of MV females as a result of fluoxetine treatment, a phenomenon we have described elsewhere.⁷⁶ This may be the result of the $SERT^{+/-}$ genotype of the MV females. In future studies, wildtype $SERT^{+/+}$ rats will have to be included in order to establish whether this is indeed a genotype * drug effect. None of the females included in the current study showed any signs of toxicity as a result of FLX. In total, 4 groups of MV females were sampled for this study: cMV-Veh (N=20), sMV-Veh (N=13), cMV-FLX (N=34) and sMV-FLX (N=25). The group sizes were uneven because we were dependent on the number of animals included in ongoing experiments. Based on the availability of fecal samples from all time points, the final number of animals selected for 16S rRNA gene sequencing for this study were 11 cMV-Veh, 8 sMV-Veh, 8 cMV-FLX and 9 sMV-FLX. Because littermates can share microbiotas, no females from the same litter were used within each group for the analysis. To this end, we randomly excluded 4 animals that had a litter

mate in the same group (IDs 997, 1076, 1113, 1727), leaving us with final sample sizes of 11 cMV-Veh, 8 sMV-Veh, 7 cMV-FLX and 6 sMV-FLX.

Fecal sample collection

Fecal samples to be sequenced were collected at GD0 (before conception), GD7, GD14, PND2, PND7, PND14 and PND21 (Figure 1b). We chose not to collect samples closer to the day of giving birth to avoid unnecessary stress. The samples were freshly collected directly from the animal between 10:00AM and 11:00AM, and precautions were taken to minimize sample contamination, such as the use of gloves and disinfection of work surfaces. The samples were placed in clean 2.0 mL Safe-Lock Eppendorf tubes (Nijmegen, The Netherlands), snap frozen in liquid nitrogen, and stored at -80 °C.




Figure 1: Overview of study design and sampling schedule. (a) Early life stress protocol. $SERT^{+/-}$ females were crossed with $SERT^{+/+}$ males, yielding nests with offspring genotypes $SERT^{+/+}$, $SERT^{+/-}$, and $SERT^{-/-}$. The $SERT^{+/-}$ females are our model of maternal vulnerability (MV). From postnatal day (PND) 2 to PND15, pups were either maternally separated for 6 hours per day (early life stress - sMV) or control handled (cMV) for 15 minutes per day. Pups were weaned at PND21. sMV- and cMV females were group housed (same treatment) until adulthood. (b) Fluoxetine treatment during pregnancy and lactation, and fecal sampling schedule. Adult sMV and cMV females ($N=14-18$ /group) were crossed with wildtype males. Throughout pregnancy and lactation, from gestational day (GD)1 until PND21, females received a daily oral injection of either 10 mg/kg fluoxetine (FLX) or methylcellulose (Veh). Thus, there were 4 groups of females: cMV-Veh, sMV-Veh, cMV-FLX, and sMV-FLX ($N=6-11$ /group). Fecal pellets for 16s rRNA gene sequencing were freshly collected before conception at GD0, during pregnancy at GD7 and GD14, at PND2, and during lactation at PND7, PND14 and PND21 ($N=192$ in total). Selected fecal samples from GD7 and PND7 were also used for metabolomic analysis ($N=4-5$ /group per time point, $N=36$ in total).

16S rRNA gene sequencing and analysis

Genomic DNA was isolated from fecal pellets using the PSP® Spin Stool DNA Kit (STRATEC Molecular GmbH, Berlin, Germany), according to the manufacturer's instructions for difficult to lyse bacteria. About 100-200 mg fecal matter per sample was used for the DNA isolation; the remainder of the sample was stored for metabolite measurements. A dual-index sequencing strategy targeting the V4 region of the 16S rRNA gene was employed, using barcoded primers for the Illumina platform, as described previously.⁷⁷ Library concentration was quantified using Qubit and an additional primer dimer clean-up step was conducted using the AMPure XP beads according to the manufacturer's protocol (Beckman Coulter, Brea, CA, USA). Sequencing was executed on a MiSeq instrument (Illumina, San Diego, CA) using 250 base paired-end chemistry at the University of Pennsylvania Next Generation Sequencing Core. For quality control purposes, a sample of the Human Microbiome Project Mock Community was included as a positive control, and water as a negative control. Quality filtering and chimera checking yielded 7,867,454 quality-filtered sequences with a mean \pm SD depth of $35,860 \pm 2560$ reads per sample. Paired-end reads were assembled and quality filtered to include sequences with a Q score ≥ 30 .

16S rRNA gene analysis was performed as described before,³⁶ using mothur v. 1.39 and QIIME version 1.9.1 (Quantitative Insights Into Microbial Ecology).^{78,79} Sequences < 248 bp and > 255 bp in length and sequences with homopolymers > 10 bp in length were removed. Operational Taxonomic Units (OTUs) at genus level were defined with 97% sequence similarity using clustering method CD-HIT. A representative sequence from every OTU containing ≥ 10 sequences was selected for downstream analyses (based on the most abundant sequence). Chimeric sequences were removed using ChimeraSlayer. Representative sequences were assigned to genera using the Ribosomal Database Project (RDP) classifier v 2.2, multiple sequence alignment was performed using PyNAST, and a phylogeny was built with FastTree. The samples were rarified to 1,000 sequences per sample before calculating diversity metrics. The Shannon diversity index was used to calculate alpha diversity, and weighted UniFrac distances were used to calculate beta diversity.

For quality control purposes, water samples and genomic DNA from abovementioned mock communities were sequenced and analyzed through the bioinformatics pipeline and the expected sequences were compared to the obtained sequences. Taxa identified as cyanobacteria or 'unclassified' at the phylum level were removed.

Analysis of microbiome data

The samples from GD7 and GD14 were grouped as pregnancy and the samples from PND7, PND14 and PND21 as lactation, since we observed no significant differences within these periods in terms of alpha diversity and beta diversity of the microbiome (Supplementary Figure 4). Conversely, the samples from PND2 were left out of the analysis, since they did not fit either category (Supplementary figure 1a, 1b). To identify the fecal microbial OTUs that differentiate between pregnancy and lactation, the machine-based learning algorithm Random Forests was used in R version 3.4.1 as previously described.^{36,80} OTU importance was ranked by the percent increase in prediction error of the model as a result of removal of that particular OTU from the model. The

resulting model, derived from cMV-Veh samples, was then applied to OTU tables from the other groups, to see how early life stress, FLX and their combination alter the microbial signature of pregnancy and lactation. The R package “gplots” was used to plot OTU relative abundances as heat maps. To predict the metabolic capacity of the gut microbiome during pregnancy and lactation, a computational approach known as Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) was used.⁸¹ This algorithm uses the 16S rRNA data to predict the total metagenomic content, and these metagenomes are then mapped onto functional Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in order to predict the full functional capacity of the microbial community, as previously described.³⁶ Random Forests were applied to the dataset of predicted metabolic pathways to identify those that shift from pregnancy to lactation in the cMV-Veh group. Then, the impact of early life stress, FLX, and their combination on the proportional representation of these predicted microbial metabolic pathways was plotted in a heat map.

Targeted metabolomics

To draw associations between bacterial community composition, predicted gut microbial metabolic capacity, and gut metabolite output, fecal metabolites were quantified in a subset of the same samples that were previously used for 16s rRNA sequencing. Budgetary consideration prevented processing of all samples. GD7 was chosen as a representative time point for pregnancy, and PND7 for lactation. Fecal samples weighing about 300 mg from 5 randomly selected animals per treatment group were used (N=36 in total). However, before analysis, samples from 2 animals were excluded to avoid having litter mates in the same group (see details above). Targeted metabolomics was performed by the Microbial Culture and Metabolomics Core as part of the PennCHOP Microbiome Program at the University of Pennsylvania via ultra-performance liquid chromatography (Acquity UPLC system, Waters Corporation, Milford, MA). For detailed methods, see Supplementary Table 1. Due to technical challenges, we were unable to acquire measurements of the amino acid tryptophan, the precursor to serotonin.

Analysis of metabolomics data

All metabolites that were detected in at least 40% of samples were included in the analysis. For these metabolites, missing values were replaced by half the minimum positive value found for that metabolite, assuming that missing values were the result of the concentration being below the detection limit. Random Forests were applied as described above to the metabolite concentration table from the cMV-Veh samples in order to reveal which individual metabolites were overrepresented during pregnancy or during lactation. The resulting model was then applied to the data from the treatment groups, and heat maps were generated. For predictive analysis, the open-access online platform MetaboAnalyst 3.0 was used for pathway analysis based on the metabolomics data.⁸² Metabolite Set Enrichment Analysis, a metabolomic version of Gene Set Enrichment Analysis, was used to investigate which sets of functionally related metabolites differ between pregnancy and lactation per treatment group.⁸³

Additional statistical methods

Microbial alpha diversity was analyzed with a t-test to assess the difference between pregnancy and lactation over all groups using R core package “stats”. Then within each period, a two-way ANOVA was used with FLX and stress as factors. Tukey’s Honest Significant Difference *post hoc* tests were used for multiple comparisons (cMV-Veh vs sMV-Veh, cMV-Veh vs cMV-FLX, sMV-Veh vs sMV-FLX, cMV-FLX vs sMV-FLX). Permutational multivariate analysis of variance using distance matrices (PERMANOVA) was used to analyze effects of pregnancy vs lactation and treatment group on weighted UniFrac distances.⁸⁴ PERMANOVA p-values were based on 999 Monte Carlo simulations. Because of the compositional nature of the data, OTU relative abundances were transformed before applying a two-way ANOVA and *post hoc* tests were as described above. First, zero values were replaced by half the minimum possible value – 0.0005 or 0.05% - and then, using R package “rgr”, relative abundances were transformed using a centered log-ratio transformation.⁸⁵ Metabolite concentrations were analyzed in the same way but untransformed. Since the OTUs and metabolites analyzed in this way differed between pregnancy and lactation in the cMV-Veh group, following from the Random Forests analysis; further statistics between periods were not conducted. A t-test was used to analyze the GD0 alpha diversity difference between cMV and sMV females. Correlation analysis was done and matrices were made using “Hmisc” and “corrplot”. The statistical significance is indicated as follows: # $p < 0.1$, * $p < 0.05$; ** $p < 0.01$; and *** $p < 0.001$, **** $p < 0.0001$. Data are presented as mean \pm SEM, except OTU relative abundance which is plotted as median \pm IQR.

Results

We examined the hypothesis that depressive-like symptoms and antidepressant treatment with FLX during pregnancy and lactation affect the maternal fecal microbiome composition and function. Maternal vulnerability (MV) rats were used, since early life stress produces depressive-like symptoms and shifts in fecal microbiome community composition in these animals (Figure 1a).^{6,42} In line with this, we observed pre-conception differences between the stressed (sMV) and the control (cMV) groups, with the sMV group showing higher alpha diversity than the cMV group (Supplementary Figure 1a, $t_{30} = -2.0709$, $p < 0.05$). This coincided with differences in Operational Taxonomic Unit (OTU) relative abundance (Supplementary Figure 1b). Then, throughout gestation and the postpartum period, sMV and cMV females were treated with FLX or Veh daily (Figure 1b). Weekly fecal pellets were collected for 16s rRNA sequencing and a subset was used for targeted metabolomic analysis in addition to sequencing (Figure 1b).

Pregnancy and lactation have distinct fecal microbial signatures

To examine whether pregnancy and lactation have distinct fecal microbial signatures, we first analyzed the 16S rRNA sequencing data in terms of microbial alpha diversity and community structure over all treatment groups. Alpha diversity was higher during pregnancy than during lactation, as expressed in the Shannon diversity index (Figure 2a, $t_{158} = 7.5845$, $p < 0.0001$). The differences in phylogenetic structure between samples were explored by assessing weighted UniFrac

distances. A separation between samples obtained during pregnancy versus lactation was revealed by Principle Coordinates Analysis (PCoA) (Figure 2b, PERMANOVA $p=0.001$).

In order to identify the bacterial signatures that underlie the observed shift in community structure between pregnancy and lactation, a machine-learning approach called Random Forests was used to analyze the data of the cMV-Veh group. This generated a model containing 28 OTUs at the genus-level, discriminating between pregnancy and lactation. A large reorganization of the microbiome composition from gestation to lactation was revealed, consistent with structural remodeling. Particularly within the *Bacteroidales* and *Clostridiales* orders, OTUs changed in their relative abundance from pregnancy to lactation (Supplementary Figure 2a).

Fluoxetine treatment alters the maternal fecal microbial signatures of pregnancy and lactation in a rat model for depressive-like behavior

To test whether early life stress, FLX, and their combination alter the observed fecal microbial signatures of pregnancy and lactation, we first compared the groups with respect to alpha- and beta diversity measures. During pregnancy, we found a main effect of early life stress on microbial alpha diversity, with the sMV groups showing a higher Shannon diversity index than the cMV groups (Figure 2a, $F_{1,60}=4.690$, $p<0.05$). *Post hoc* analysis revealed no significant differences between groups. During lactation, there was a significant FLX * early life stress interaction effect (Figure 2a, $F_{1,92}=5.256$, $p<0.05$) and a trend towards a main effect of stress ($F_{1,92}=2.784$, $p=0.0986$). *Post hoc* analysis revealed that the Shannon diversity index was significantly higher in the sMV- than in the cMV group during lactation ($p<0.05$). In terms of microbial community structure, the treatment groups dissociated based on PCoA of the weighted UniFrac distances (Supplementary Figure 2b, PERMANOVA $p=0.001$). In particular, microbial community structure in the sMV-FLX group differed from the structure in the sMV-Veh group, both during pregnancy and lactation (Figure 2c, pregnancy sMV-Veh vs sMV-FLX PERMANOVA $p<0.05$, lactation sMV-Veh vs sMV-FLX PERMANOVA $p=0.001$). This suggests that, in addition to the dynamic restructuring of the fecal microbiome across pregnancy and lactation, fluoxetine treatment modulated community structure of the fecal microbiota in the sMV females during these periods.

Next, the relative abundance of the 28 OTUs constituting the Random Forests-generated model discriminating between pregnancy and lactation in the cMV-Veh group was examined for the treatment groups. Globally, the pattern of OTUs distinguishing between pregnancy and lactation in the treatment groups was similar to that of the cMV-Veh group (Figure 2d). However, specific OTUs showed variations in their relative abundance dependent on treatment as tested by two-way ANOVAs (early life stress * FLX) within pregnancy and lactation (Figure 2e; Supplementary Figure 2c). For instance, the 2 OTUs with the largest contribution to the accuracy of the Random Forests model, *Bacteroides* and *Prevotella* from the *Bacteroidales* order, were sensitive to FLX treatment. *Bacteroides* relative abundance was lower in the FLX groups than the Veh-treated groups during pregnancy (Figure 2e, main effect of FLX, $F_{1,60}=13.206$, $p<0.001$). *Post hoc* testing revealed that specifically the cMV-FLX group had a lower relative abundance of *Bacteroides* than the cMV-Veh group ($p<0.01$). During lactation, a trend for a FLX * early life stress interaction was found for





Figure 2: Fluoxetine treatment alters the microbiome during pregnancy and lactation in rats with a depressive-like phenotype. (a) Microbial alpha diversity. The Shannon diversity index was used as a measure of alpha diversity. A *t*-test was performed to assess the overall difference between pregnancy and lactation. Within each period, a two-way ANOVA was performed with early life stress and FLX as factors. (b) Structure of the microbial communities during pregnancy and lactation. Communities were clustered using PCoA of the weighted UniFrac distance matrix. Each point corresponds to the microbial community of one sample that was collected during pregnancy or lactation. The percentage of variation explained by the PC is indicated on the axes. Colors correspond to period; all samples were grouped within pregnancy and lactation. (c) The effect of FLX on the structure of the sMV microbiome during pregnancy and lactation. Communities were clustered using PCoA of the weighted UniFrac distance matrix. Each point corresponds to the microbial community of one sample that was collected during pregnancy (upper graph) or lactation (lower graph). The percentage of variation explained by the PC is indicated on the axes. Colors correspond to group; sMV-Veh in white and sMV-FLX in gray.



(d) Heatmap of relative abundances of Random Forests-identified OTUs distinguishing between pregnancy and lactation. Random Forests was used to identify the microbial OTUs that had the highest predictive value for distinguishing between pregnancy and lactation in the cMV-Veh group. The heatmap depicts the relative abundance of these 28 OTUs during pregnancy and lactation for all groups, ordered by unsupervised clustering. (e) Relative abundance of selected Random Forests-identified OTUs. Two-way ANOVAs within pregnancy and lactation were used to analyze OTU relative abundance, with early life stress and FLX as factors. Note: this analysis was performed on centered log-ratio transformed data (see Methods). N=12-22 samples/group from pregnancy (N=64 in total), N=18-33/group from lactation (N=96 in total).

Bacteroides relative abundance ($F_{1,92}=3.774$, $p=0.0551$), with a trend for a lower relative abundance in the sMV-FLX group than in the sMV-Veh group ($p=0.0764$). The opposite effect of FLX was found for *Prevotella* where a main effect of FLX on *Prevotella* relative abundance was found during pregnancy ($F_{1,60}= 16.488$, $p<0.001$). Specifically, there was a trend for higher *Prevotella* relative abundance in the cMV-FLX than in the cMV-Veh group ($p=0.0944$), and a statistically significant higher *Prevotella* relative abundance in the sMV-FLX group than in the sMV-Veh group ($p<0.01$). During lactation, a FLX * early life stress interaction effect was found ($F_{1,92}= 8.520$, $p<0.01$), as well as a main effect of FLX ($F_{1,92}= 4.249$, $p<0.05$). *Post hoc* testing revealed a higher *Prevotella* relative abundance in the sMV-FLX group than in the sMV-Veh group ($p<0.01$) and the cMV-FLX group ($p<0.05$), reaching almost 25% of the total relative abundance. Similarly, there was a main effect of FLX during pregnancy on *Ruminococcus* relative abundance ($F_{1,60}= 26.166$, $p<0.0001$), where both the cMV-FLX group relative to the cMV-Veh group ($p<0.05$) as well as the sMV-FLX group relative to the sMV-Veh group ($p<0.001$) had a higher relative abundance of *Ruminococcus*. During lactation, a FLX * early life stress interaction was found ($F_{1,92}= 4.245$, $p<0.05$), and a trend for a main effect of FLX ($F_{1,92}= 3.575$, $p=0.0618$). *Post hoc* analysis revealed a higher *Ruminococcus* relative abundance in the sMV-FLX group relative to the sMV-Veh group ($p<0.05$). Early life stress by itself did not have effects as striking as FLX, although during pregnancy relative abundance of *Adlercreutzia* and UC *Lachnospiraceae* were higher and *Lactobacillus* lower in stressed dams than in controls (Supplementary Figure 2c).

Considering that OTUs within a community display co-occurrence and co-exclusion relationships,⁴³ we performed a correlation analysis to look at these relationships within our samples, regardless of time of sampling or treatment. A correlation matrix between the 28 selected OTUs revealed that *Prevotella* was negatively correlated with a cluster consisting mainly of *Clostridiales* and *Desulfovibrionales* (Supplementary Figure 2d). *Ruminococcus* was the exception within the *Clostridiales*, being positively correlated with *Prevotella*.

Together, these results confirm that pregnancy and lactation are distinct with regard to fecal microbiota diversity and composition. Although early life stress increased alpha diversity during lactation, there were limited effects of early life stress alone on either microbial community structure or on the relative abundance of OTUs resulting from our Random Forests model. However, FLX impacted community structure during pregnancy and lactation, as well as the relative abundance of a number of OTUs selected for their ability to distinguish between pregnancy and lactation. FLX in combination with early life stress had the largest effects on the maternal microbiome.

Pregnancy and lactation have distinct fecal metabolic signatures

Bacterial communities metabolize and synthesize a number of metabolites that are essential for both dam and offspring. Shifts in bacterial community composition and predictive function may suggest alterations in the capacity of these communities to synthesize or metabolize these metabolites. We first performed PICRUSt predictive analysis on the OTU data to explore the hypothesis that the functional potential of pregnancy and lactation is different, since they have different microbial

signatures. To this end, Random Forests analysis was performed on PICRUSt-generated data from the cMV-Veh group. Nine KEGG pathways were significantly changed across pregnancy and lactation, including the pathway of lysine biosynthesis; the pathway of alanine, aspartate, and glutamate metabolism; and the pathway of arginine and proline metabolism (Figure 3a; Supplementary Figure 3a). Overall, pathways related to amino acid synthesis and metabolism were among the metabolic pathways best able to characterize the difference in the predicted function of the maternal bacterial community during pregnancy vs lactation.

To determine whether this altered predictive metabolic capacity of the microbiome was associated with actual metabolite availability, we measured the concentration of amino acids, bile acids, and short-chain fatty acids in a subset (N=4-5 per group in pregnancy and lactation) of fecal pellets previously used for 16S rRNA sequencing (Supplementary Table 1). Corresponding to the microbiome results, principle component analysis (PCA) revealed a clear distinction in metabolic profile between samples obtained during pregnancy versus lactation (Figure 3b, upper graph).

To reveal the metabolic signatures of pregnancy and lactation, Random Forests analysis was performed on the metabolite data from the cMV-Veh group. Fourteen metabolites were included in the resulting model to distinguish between pregnancy and lactation (Supplementary Figure 3b). Most of them were amino acids, and 11 out of 14 metabolites were higher in concentration during pregnancy than during lactation (Figure 3c). For instance, the amino acids isoleucine and methionine had higher concentrations during pregnancy than during lactation, while proline concentrations were higher during lactation than during pregnancy (Supplementary Figure 3c). The bile acids deoxycholic acid and taurochenodeoxycholic acid were both higher in concentration during pregnancy than during lactation. Of the short-chain fatty acids included in the Random Forests model, isocaproic acid concentrations were very low during pregnancy, whereas isovaleric acid concentrations were low during lactation. Overall, the metabolomic results were consistent with the microbiome findings and the predictive functional analysis in discriminating between pregnancy and lactation and pointing towards amino acids as being central to this shift.

Fluoxetine treatment alters maternal fecal metabolite availability during pregnancy and lactation in a rat model for depressive-like behavior

To investigate whether early life stress, FLX and their combination affect the abovementioned fecal metabolic signatures of pregnancy and lactation as observed in the cMV-Veh group, we compared these groups with respect to predicted- and measured metabolic data. The effects of early life stress and FLX on the abundance of predictive pathways were mixed, with the sMV-FLX group having generally the lowest predicted abundance of these metabolic pathways (Figure 3a). Visual inspection of the PCA graph based on the metabolite concentration table revealed no clear effect of early life stress or FLX treatment (Figure 3b, lower graph).

Next, the concentrations of the 14 metabolites included in the Random Forests-generated model discriminating between pregnancy and lactation in the cMV-Veh group were examined for the treatment groups. Similar to the microbiome results, the overall pattern of metabolite availability changes between pregnancy and lactation was similar in all groups (Figure 3c). However, fecal





Figure 3: Fluoxetine alters fecal metabolite availability during pregnancy and lactation in rats with a depressive-like phenotype. (a) Heatmap of Random Forests-identified PICRUSt-generated KEGG pathways distinguishing between pregnancy and lactation. Z-scores are depicted of the abundance of the 9 identified pathways for all groups. The pathways are ordered by unsupervised clustering. (b) Structure of the metabolomic composition during pregnancy and lactation. Samples were clustered using PCA of the metabolomics concentration table. Each point corresponds to the metabolic capacity of one sample that was collected during pregnancy or lactation. The percentage of variation explained by the PC is indicated on the axes. Colors correspond to period in the upper graph, and to group in the lower graph. (c) Heatmap of Random Forests-identified metabolite concentrations distinguishing between pregnancy and lactation. Z-scores are depicted of the concentrations of the 14 identified metabolites for all groups. (d) Concentrations of selected amino acids. Two-way ANOVAs within pregnancy and lactation were used to analyze metabolite concentration, with early life stress and FLX as factors.



(e) Metabolite Set Enrichment Analysis of pregnancy vs lactation per group. Only the pathways that were significantly altered between pregnancy and lactation are shown here; the full list of metabolic pathways is shown in Supplementary Figure 3e. For a: $N=12-22$ samples/group from pregnancy ($N=64$ in total), $N=18-33$ /group from lactation ($N=96$ in total). For b-e: $N=4-5$ /group from pregnancy ($N=18$ in total), $N=4-5$ /group from lactation ($N=18$ in total).

amino acid concentrations were affected by FLX treatment (Figure 3d, Supplementary Figure 3c). There was a trend towards a main effect of FLX on aspartic acid concentrations during pregnancy ($F_{1,16}=4.090$, $p=0.0602$) and a significant main effect during lactation ($F_{1,16}=9.689$, $p<0.01$). There was also a trend towards a main effect of early life stress on aspartic acid concentration during lactation ($F_{1,16}=3.868$, $p=0.0668$). Between-group *post hoc* analysis revealed a significantly lower concentration of aspartic acid in the sMV-FLX group relative to the sMV-Veh group ($p<0.05$). For serine concentrations, we found a FLX * early life stress interaction effect during pregnancy ($F_{1,16}=5.868$, $p<0.05$), as well as a main effect of FLX ($F_{1,16}=25.314$, $p<0.001$). In particular, there was a trend for lower serine concentrations in the cMV-Veh group than in the sMV-Veh group ($p=0.0565$), and significantly lower concentrations of serine in the sMV-FLX group than in the sMV-Veh group ($p<0.001$). For threonine concentrations, we found a trend for a main effect of FLX during pregnancy ($F_{1,16}=3.598$, $p=0.076$), where the FLX groups show decreased threonine levels.

Since, by restricting ourselves to Random Forests-identified metabolites, we might miss interesting effects of our treatments on metabolites that do not differ between pregnancy and lactation, we decided to also analyze those metabolites as well with two-way ANOVAs within pregnancy and lactation (Supplementary Figure 3d). We found that FLX was associated with lower concentrations of the amino acid glutamic acid during lactation ($F_{1,16}=8.200$, $p<0.05$), and with lower levels of the bile acids betamuricholic acid ($F_{1,16}=5.543$, $p<0.05$) and omegamuricholic acid ($F_{1,16}=7.002$, $p<0.05$) during pregnancy. Interestingly, within the short-chain fatty acids, isobutyric acid concentrations were decreased by FLX during pregnancy (trend, $F_{1,16}=3.952$, $p=0.0642$) and during lactation ($F_{1,16}=5.902$, $p<0.05$), while butyric acid was increased by FLX during lactation ($F_{1,16}=5.019$, $p<0.05$).

Next, we used Metabolite Set Enrichment Analysis (MSEA) to identify the fecal metabolite sets that were enriched during either pregnancy or lactation. In the cMV-Veh group, there were several pathways that significantly differed between these two periods, again containing amino acid-related pathways such as glycine and serine metabolism (Figure 3e; Supplementary Figure 3e). Then, we performed MSEA on the sMV-Veh, cMV-FLX and sMV-FLX data to determine which metabolites involved in specific metabolic processes were enriched in either pregnancy or lactation. The sMV-Veh group, like the cMV-Veh group, contained a number of metabolite sets that distinguished between pregnancy and lactation, such as methionine metabolism, and glycine and serine metabolism. In contrast, in the cMV-FLX and sMV-FLX groups no metabolite sets were identified that differed significantly between pregnancy and lactation. Thus, fluoxetine treatment lowered the fecal concentrations of several key amino acids during the dynamic periods of pregnancy and lactation in our model for maternal depressive-like symptoms. In addition, fluoxetine treatment abolished the differences in MSEA-identified pathways that distinguished the fecal metabolome during pregnancy from lactation as observed in the Veh-treated groups.




Figure 4: Correlation matrix of metabolites and OTUs throughout pregnancy and lactation. Spearman's rank correlations were determined between the 14 Random Forests-identified metabolites and the 28 Random Forests-identified OTUs. The circles represent the correlation between each metabolite and OTU. The size of the circle increases with decreasing p-value-, and the color of the circle corresponds to the p-value of the correlation (the strength of the correlation). Only significant ($p < 0.05$) correlations are plotted, and only the OTUs with at least 1 significant correlation are shown here. The matrix is ordered by hierarchical clustering. $N=4-5/\text{group}$ from pregnancy ($N=18$ in total), $N=4-5/\text{group}$ from lactation ($N=18$ in total).

The relative abundances of fecal bacterial taxa correlate with metabolite concentrations

Finally, we generated a correlation matrix to further explore the link between the composition of the microbiome and the availability of metabolites (Figure 4). We collapsed all treatment groups in this analysis to capture the full range of variation in both OTU abundance and metabolite concentrations. A cluster consisting of OTUs from the *Clostridiales* (including *UC Peptococcaceae*, *Clostridia*; other and *Oscillospira*) and *Desulfovibrionales* (*Desulfovibrio* and *UC Desulfovibrionaceae*) orders was positively correlated with amino acid concentrations. Showing almost the reverse pattern, the relative abundance of *Prevotella* was negatively correlated with

availability of isobutyric acid and a collection of amino acids; alanine, isoleucine, glycine, methionine, and serine. Associating to a different set of metabolites, the relative abundance of *Ruminococcus* was inversely correlated with concentrations of aspartic acid and some bile acids; betamuricholic acid, omegamuricholic acid, and alphamuricholic acid. Overall, the OTUs that were most affected in relative abundance by FLX treatment (*Bacteroides*, *Prevotella* and *Ruminococcus*) were correlated with amino acid availability.

Discussion

Our study shows that antidepressant treatment with fluoxetine (FLX) during pregnancy and lactation disrupts metabolite availability in a rat model for maternal depressive-like symptoms, possibly through alterations in bacterial community composition and function. In short, maternal vulnerability (MV) female rats were exposed to early life stress (sMV). In adulthood, sMV and control (cMV) females were treated throughout gestation and lactation with the SSRI FLX or vehicle (Veh). Fecal samples were collected for 16s rRNA sequencing and targeted metabolomics.

We first explored the distinct fecal microbial signatures of pregnancy and lactation in cMV-Veh females. Human studies showed a remodeling of the microbiome from the first- to the third trimester, with changes in diversity and composition.⁴⁴ Similarly, the maternal microbiome in mice changes from early to late pregnancy.³⁶ Paradoxically, here we observed stability of the microbiome over pregnancy, potentially related to the fact that we had no samples during the first week of gestation, only starting at GD7. Likewise, a human study in which fecal sampling did not cover the first few weeks post-fertilization reported stability of the microbiome over the course of pregnancy.⁴⁵ In addition, stability of the human microbiome over lactation has been observed.⁴⁶ We complement these studies by instead defining distinct microbial signatures associated with pregnancy versus lactation, periods with dynamic hormonal, immunological and metabolic changes.³⁵ Specifically, we showed that the transition from pregnancy to lactation in rats was characterized by a decrease in alpha diversity and a large reorganization of the structure of the fecal microbial community, with an increase in *Prevotella* at the cost of *Bacteroides* within the *Bacteroidales*, and an increase in *Ruminococcus* at the cost of other *Clostridiales* OTUs.

We then hypothesized that early life stress and FLX alter the observed fecal microbial signatures of pregnancy and lactation. It has been shown repeatedly that early life stress by maternal separation in rodents produces long-term effects on the gut and its microbiome.^{47–52} We showed here that adult sMV females had a higher fecal alpha diversity than cMV females pre-conception, during pregnancy and during lactation. We have previously found this tendency in young rats,⁶ suggesting that our stress protocol induces an immediate and life-long increase in microbial alpha diversity. This is surprising, since other studies of early life stress by maternal separation in rodents have reported a decrease in alpha diversity,^{21,51} or no effect.⁵² In fact, a more diverse microbiome is usually positively associated with health.⁵³ However, it likely depends on the identity of the bacteria that make a more diverse community, whether health outcomes are positive or negative. Stressed females had a reduced relative abundance of *Lactobacillus* during pregnancy, a microbe known for

its beneficial health effects.¹⁴ Early life stress did not affect the overall composition of the maternal microbiome like it did pre-conception, possibly due to a masking effect by pregnancy and lactation.

Treatment with the SSRI fluoxetine, however, was associated with major alterations in the maternal fecal microbiome. Human population-based studies also show that SSRI use associates with distinct characteristics of the microbiome.^{16,22,23} Moreover, recent experiments showed that FLX alters the gut microbiota in rats,^{24,27} and in mice^{25,26,28,29}. Interestingly, the specific bacteria underlying this difference do not match between studies (Table 1). Whereas we found significant increases in *Prevotella* and *Ruminococcus* relative abundance during pregnancy and lactation in FLX-treated rats, Cusotto et al report a complete depletion of some *Prevotella* OTUs in FLX-treated male rats,²⁴ and Lukić et al found many *Ruminococcaceae* OTUs to be lower in FLX- and escitalopram-treated mice relative to controls.²⁶ Whether inconsistencies like these are due to differences in life stage and sex – none of the other studies was done in females in the perinatal period – or other factors such as genetic background remains to be investigated. In addition, it is not clear how SSRIs might achieve their effect on the microbiota. *In vitro* studies suggest that SSRIs possess antimicrobial properties,^{24,30,31} possibly by inhibiting efflux pumps or by acting on bacterial homologs of the SERT or biogenic amine receptors.^{31,54,55} Alternatively, it is possible that SSRIs alter the intestinal habitat through their known impact on host SERT functioning and gut homeostasis.³ Our results here confirm that SSRIs have the potential to modulate the fecal microbiome during pregnancy and lactation in rats.

Table 1: Overview of changes in the gut microbiome after FLX treatment in rodent studies.

Study	Study design	Highlighted findings FLX-treated vs vehicle-treated animals	Corresponds to current results?
Cusotto et al. 2019 ²⁴	Male rats, 28 days of 10 mg/kg/day, in drinking water	Alpha diversity: no significant difference OTU abundance: depletion of <i>Prevotella</i> 7 and 9	Yes No; we found increases in <i>Prevotella</i>
Lyte et al., 2019 ²⁵	Male mice, 29 days of 20 mg/kg/day, oral gavage	Alpha diversity: no significant difference OTU abundance: decrease in S24-7 (<i>Bacteroidales</i>)	Yes Potentially; we found decreases in several <i>Bacteroidales</i> OTUs
Lukić et al. 2019 ²⁶	Male mice, 21 days of 10 mg/kg/day, i.p. injections	Alpha diversity: decrease OTU abundance: decrease in <i>Ruminococcus</i>	No No
Zhu et al. 2019 ²⁷	Male rats, 21 days of 2 mg/kg/day, oral gavage, daily stress	Alpha diversity: no significant difference OTU abundance: <i>Prevotellaceae</i> Ga6A1 decreased, and <i>Ruminoclostridium</i> 6 and <i>Ruminococcaceae</i> NK4A214 increased	Yes Potentially; we found increases in <i>Ruminococcus</i>
Fung et al. 2019 ²⁸	Male and female mice, 7 days of 10 mg/kg/day, oral gavage	OTU abundance: decrease in <i>Turicibacter</i>	No (data not shown)
Sun et al. 2019 ²⁹	Male mice, 21 days of 12 mg/kg/day, oral gavage, daily stress	Alpha diversity: no significant difference OTU abundance: decrease in <i>Bacteroides</i>	Yes Yes

Since we have previously shown that early life stress interacts with a reduction in serotonin transporter availability to inflate its effect on the gut microbiome composition, we expected our sMV-FLX animals to show the largest effects.⁶ Indeed, FLX significantly affected overall bacterial community structure only in sMV females. It might be that the sMV microbiome, belonging to a depressive-like host, is more unstable and sensitive to disruptions than the cMV microbiome,

especially during the dynamic perinatal period. In this proposed double-hit model, it is the combination of early life stress and FLX that shifts the balance in the gut microbial community. Analogously, another study using early life stress by maternal separation reported a change in the gut microbiome only after a second stressor in adulthood,⁵⁶ strengthening this double-hit hypothesis.

Next, we tested the hypothesis that the effects of FLX on the sMV maternal microbiome during pregnancy and lactation would be reflected in an altered functional output of the microbial community. It was shown recently that fluoxetine treatment in rats is associated with several altered metabolic pathways in feces, including neurotransmitter synthesis, fatty acid metabolism, and bile acid metabolism.⁵⁷ It is also known that gut microbes greatly affect host plasma and fecal metabolite availability.^{32,33} Microbes modify and produce amino acids, bile acids and short-chain fatty acids that become available to the host.⁵⁸ Thus, we measured the concentrations of these metabolites in a subset of fecal samples that were used for microbiome analysis. Most metabolites were higher in concentration during pregnancy than during lactation, reflecting either greater metabolite intake or production during pregnancy, or more breakdown or transfer to the offspring during lactation. sMV-FLX animals had lower levels of serine during pregnancy, and lower levels of aspartic acid during lactation than sMV-Veh animals. Interestingly, amino acids that were relatively low in FLX-treated animals, such as threonine, can serve as precursors of microbial short-chain fatty acid synthesis.⁵⁹ We found a corresponding decrease in isobutyric acid concentration as a result of FLX treatment. Cussotto et al. also found a lower mean isobutyric acid concentration in the feces of FLX-treated animals than in controls, although this was not a statistically significant effect.²⁴ Overall, FLX treatment was associated with lower fecal availability of amino acids, most strongly in sMV females, pointing to a potential role for FLX in altering bacterial nitrogen regulation.⁶⁰

Finally, to link microbes to metabolites, we generated correlation matrices both within the bacterial taxa that changed from pregnancy to lactation, as well as between the relative abundance of these taxa and metabolite concentrations that changed from pregnancy to lactation. We found that the relative abundance of *Prevotella*, enhanced in the sMV-FLX group, was negatively correlated with a cluster of *Clostridiales* and *Desulfovibrionales* genera. Interestingly, these same *Clostridiales* and *Desulfovibrionales* OTUs were positively associated with availability of amino acids (with the exception of aspartic acid). Previous literature describes that some of the most prevalent amino acid fermenting microbes indeed belong to the *Clostridiales* and *Proteobacteria* taxa.⁶¹ The second highly abundant OTU in the sMV-FLX group, *Ruminococcus*, was negatively correlated to the primary (beta-muricholic acid) and secondary (omega-muricholic acid) bile acids that were in pregnancy in the feces of FLX treated females, potentially mediated by a decrease in *Lactobacillus* relative abundance. Bile acids have been reported to induce serotonin release from enterochromaffin cells,⁶² hinting to a potential negative feedback mechanism. The associations we report here yield a working hypothesis that FLX during the perinatal period – at least in an animal model for depressive-like behavior – tips the balance toward higher abundance of *Prevotella* and *Ruminococcus* and lower abundance of amino acid-fermenting and bile acid-associated OTUs, leading to lower fecal availability of these metabolites. Since *Prevotella* and *Ruminococcus* are known mucin-degraders,⁶³

and breakdown of the protective mucin layer of the gastrointestinal tract could have health effects for the host, it would be interesting to study whether mucin-degrading enzymes are enriched in FLX-treated animals in the future.

This study has several limitations. Using the 16S rRNA marker gene sequencing approach, our analysis was constrained to the genus level. Species within the same genus, however, might differ in their capacity to produce metabolites,⁶⁴ which creates a limitation in finding and interpreting associations between OTUs and metabolites in this study. In addition, we are aware that the microbiome and its functional capacity varies across locations in the gastrointestinal tract,⁶⁵ whereas we only used fecal samples. In fact, the effect of FLX on the microbiome likely varies along the gastrointestinal tract, since fluoxetine is absorbed almost completely.⁶⁶ However, FLX can still be recovered from feces as was shown in humans,⁶⁷ and in this way could have an effect even on distal portions of the gut. Lastly, since we only measured metabolite concentrations in feces, it is still unclear whether and how the effect of FLX on the gut microbiome is associated with their systemic availability.

The benefits of performing microbiome research on laboratory rodents as opposed to humans deserve mentioning here. For example, diet composition could be kept stable throughout the study, whereas diet composition changes considerably from pre-conception to pregnancy in humans and even short-term changes in diet are known to affect the gut microbiome.^{68,69} In addition, we are able to study the independent effect of SSRI use in rodents, as well as its interactions with a depressive-like phenotype.⁴⁰ At the moment, there is a paucity of studies into the effect of SSRI on the microbiome from clinical studies on depression or animal studies mimicking this condition. For instance, it is unclear whether any effects SSRIs might have on the microbiome are part of their therapeutic potential or should rather be seen as side effects.⁷⁰ However, the biggest asset of the current study is our ability to link changes to the microbiome and its predicted functional capacity to changes in metabolite availability.

In conclusion, we showed here that fluoxetine treatment modulated key aspects of maternal microbial community dynamics and metabolite output, mainly in sMV females. Our results add to the growing body of research linking serotonin signaling to the gut microbiome, as well as to the emerging awareness that the maternal microbiome is plastic and vulnerable to environmental and pharmacological insults. Maternal depression and SSRI use during pregnancy are both associated with detrimental developmental outcomes in offspring, such as lower birth weight, delayed motor development, and increased anxiety.⁷¹ Future studies will assess whether and to what extent the maternal gut microbiome and metabolome might mediate these effects. Amino acids play essential roles in both homeostatic physiology in adults as well as in development and survival of the fetus.³⁴ Microbial molecules have been shown to transfer from mother to offspring to support the development of the brain and the immune system, emphasizing their importance.^{72,73} If the dampening effect of SSRI treatment on fecal amino acid concentrations is replicable, and if these concentrations correlate with plasma levels and with maternal and offspring health outcomes, modification of the maternal microbiome (by prebiotics or probiotics) or dietary supplementation of amino acids (i.e. postbiotics) alongside SSRI treatment might be explored as interventions.

Ethics approval

The animal study was approved by the Institutional Animal Care and Use Committee at the University of Groningen, and was conducted in accordance with the institutional guidelines and the Law on Animal Experiments.

Availability of data and material

The sequencing dataset supporting the conclusions of this article is available in the European Nucleotide Archive, accession number PRJEB30296 (ERP112729).

Disclosure of interest

The authors declare no competing interests.

Acknowledgements

We thank Judith Swart, Wanda Douwenga and Christa Reitzema-Klein for their assistance with the early life stress procedure, drug administration and sample collection.

Funding

JDAO was supported by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska Curie Individual Fellowship under Grant 660152-DEPREG; and NARSAD young investigator grant under Grant 25206. ASR was supported by a scholarship awarded by the Fulbright Center The Netherlands. TLB was supported by the National Institutes of Mental Health under Grant numbers P50-MH099910, MH 104184, MH 091258, MH 087597, MH 073030, and MH 108286. EJ was supported by the National Institutes of Health National Research Service Award F32 under Grant MH 109298.

References

1. Coppen, A. The biochemistry of affective disorders. *Br. J. Psychiatry* **113**, 1237–1264 (1967).
2. Claassen, V., Davies, J. E., Hertting, G. & Placheta, P. Fluvoxamine, a Specific 5-Hydroxytryptamine Uptake Inhibitor. *Br. J. Pharmacol.* **60**, 505–516 (1977).
3. Spohn, S. N. & Mawe, G. M. Non-conventional features of peripheral serotonin signalling-the gut and beyond. *Nat. Rev. Gastroenterol. Hepatol.* **14**, 412–420 (2017).
4. Gershon, M. D. & Tack, J. The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. *Gastroenterology* **132**, 397–414 (2007).
5. Yano, J. M. *et al.* Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell* **161**, 264–276 (2015).
6. El Aidy, S. *et al.* Serotonin Transporter Genotype Modulates the Gut Microbiota Composition in Young Rats, an Effect Augmented by Early Life Stress. *Front. Cell. Neurosci.* **11**, 1–12 (2017).
7. Singhal, M. *et al.* Serotonin Transporter Deficiency is Associated with Dysbiosis and Changes in Metabolic Function of the Mouse Intestinal Microbiome. *Sci. Rep.* **9**, 1–11 (2019).
8. Oleskin, A. V., Kirovskaia, T. A., Botvinko, I. V & Lysak, L. V. [Effect of serotonin (5-hydroxytryptamine) on the growth and differentiation of microorganisms]. *Mikrobiologiya* **67**, 305–12
9. Knecht, L. D. *et al.* Serotonin Activates Bacterial Quorum Sensing and Enhances the Virulence of *Pseudomonas aeruginosa* in the Host. *EBioMedicine* **9**, 161–169 (2016).


10. Naseribafrouei, A. *et al.* Correlation between the human fecal microbiota and depression. *Neurogastroenterol. Motil.* **26**, 1155–1162 (2014).
11. Jiang, H. *et al.* Altered fecal microbiota composition in patients with major depressive disorder. *Brain. Behav. Immun.* **48**, 186–194 (2015).
12. Zheng, P. *et al.* Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. *Mol. Psychiatry* 1–11 (2016). doi:10.1038/mp.2016.44
13. Kelly, J. R. *et al.* Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J. Psychiatr. Res.* **82**, 109–118 (2016).
14. Aizawa, E. *et al.* Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. *J. Affect. Disord.* **202**, 254–257 (2016).
15. Chen, Z. *et al.* Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder. *Neuroreport* **29**, 417–425 (2018).
16. Valles-Colomer, M. *et al.* The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat. Microbiol.* **4**, 623–632 (2019).
17. Park, A. J. *et al.* Altered colonic function and microbiota profile in a mouse model of chronic depression. *Neurogastroenterol. Motil.* **25**, (2013).
18. Marin, I. A. *et al.* Microbiota alteration is associated with the development of stress- induced despair behavior. *Nat. Publ. Gr.* 1–10 (2017). doi:10.1038/srep43859
19. Golubeva, A. V *et al.* Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. *Psychoneuroendocrinology* **60**, 58–74 (2015).
20. Wong, M.-L. *et al.* Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. *Mol. Psychiatry* **21**, 1–9 (2016).
21. O'Mahony, S. M. *et al.* Early Life Stress Alters Behavior, Immunity, and Microbiota in Rats: Implications for Irritable Bowel Syndrome and Psychiatric Illnesses. *Biol. Psychiatry* **65**, 263–267 (2009).
22. Jackson, M. A. *et al.* Gut microbiota associations with common diseases and prescription medications in a population-based cohort. *Nat. Commun.* **9**, 1–8 (2018).
23. Zhernakova, A. *et al.* Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science (80-.)*. **352**, 565–569 (2016).
24. Cusotto, S. *et al.* Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. *Psychopharmacology (Berl)*. **236**, 1671–1685 (2019).
25. Lyte, M., Daniels, K. M. & Schmitz-Esser, S. Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects. *PeerJ* **7**, e6199 (2019).
26. Lukić, I. *et al.* Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. *Transl. Psychiatry* **9**, 133 (2019).
27. Zhu, H.-Z. *et al.* Xiaoyaosan improves depressive-like behavior in rats with chronic immobilization stress through modulation of the gut microbiota. *Biomed. Pharmacother.* **112**, 108621 (2019).
28. Fung, T. C. *et al.* Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. *Nat. Microbiol.* (2019). doi:10.1038/s41564-019-0540-4
29. Sun, L. *et al.* Fluoxetine ameliorates dysbiosis in a depression model induced by chronic unpredicted mild stress in mice. *Int. J. Med. Sci.* **16**, 1260–1270 (2019).
30. Muñoz-Bellido, J. L., Muñoz-Criado, S. & García-Rodríguez, J. A. In-vitro activity of psychiatric drugs against Corynebacterium urealyticum (Corynebacterium group D2). *J. Antimicrob. Chemother.* **37**, 1005–1009 (1996).
31. Bohnert, J. A., Szymaniak-Vits, M., Schuster, S. & Kern, W. V. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. *J. Antimicrob. Chemother.* **66**, 2057–2060 (2011).
32. Wikoff, W. R. *et al.* Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 3698–703 (2009).
33. Marcobal, A. *et al.* A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. *ISME J.* **7**, 1933–1943 (2013).

34. Herrera, E. Metabolic adaptations in pregnancy and their implications for the availability of substrates to the fetus. *Eur. J. Clin. Nutr.* **54**, S47–S51 (2000).
35. Nuriel-Ohayon, M., Neuman, H. & Koren, O. Microbial changes during pregnancy, birth, and infancy. *Front. Microbiol.* **7**, 1–13 (2016).
36. Jašarević, E., Howard, C. D., Misis, A. M., Beiting, D. P. & Bale, T. L. Stress during pregnancy alters temporal and spatial dynamics of the maternal and offspring microbiome in a sex-specific manner. *Sci. Rep.* **7**, 44182 (2017).
37. Gohir, W. *et al.* Pregnancy-related changes in the maternal gut microbiota are dependent upon the mother's periconceptional diet. *Gut Microbes* **0976**, 310–320 (2015).
38. Khan, I. *et al.* Metagenomic analysis of antibiotic-induced changes in gut microbiota in a pregnant rat model. *Front. Pharmacol.* **7**, 1–11 (2016).
39. O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G. & Cryan, J. F. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav. Brain Res.* **277**, 32–48 (2015).
40. Olivier, J. D. A., Åkerud, H. & Sundström Poromaa, I. Antenatal depression and antidepressants during pregnancy: Unraveling the complex interactions for the offspring. *Eur. J. Pharmacol.* **753**, 257–262 (2015).
41. Hechler, C. *et al.* Association between Psychosocial Stress and Fecal Microbiota in Pregnant Women. *Sci. Rep.* **9**, 1–10 (2019).
42. Houwing, D. J., Ramsteijn, A. S., Riemersma, I. W. & Olivier, J. D. A. Maternal separation induces anhedonia in female heterozygous serotonin transporter knockout rats. *Behav. Brain Res.* **356**, 204–207 (2019).
43. Faust, K. *et al.* Microbial co-occurrence relationships in the Human Microbiome. *PLoS Comput. Biol.* **8**, (2012).
44. Koren, O. *et al.* Host remodeling of the gut microbiome and metabolic changes during pregnancy. *Cell* **150**, 470–480 (2012).
45. DiGiulio, D. B. *et al.* Temporal and spatial variation of the human microbiota during pregnancy. *Proc. Natl. Acad. Sci.* **112**, 11060–11065 (2015).
46. Jost, T., Lacroix, C., Braegger, C. & Chassard, C. Stability of the maternal gut microbiota during late pregnancy and early lactation. *Curr. Microbiol.* **68**, 419–427 (2014).
47. Bailey, M. T. & Coe, C. L. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. *Dev. Psychobiol.* **35**, 146–155 (1999).
48. De Palma, G. *et al.* Microbiota and host determinants of behavioural phenotype in maternally separated mice. *Nat. Commun.* **6**, 7735 (2015).
49. Pusceddu, M. M. *et al.* N-3 polyunsaturated fatty acids (PUFAs) reverse the impact of early-life stress on the gut microbiota. *PLoS One* **10**, 1–13 (2015).
50. O'Mahony, S. M., Hyland, N. P., Dinan, T. G. & Cryan, J. F. Maternal separation as a model of brain-gut axis dysfunction. *Psychopharmacology (Berl)*. **214**, 71–88 (2011).
51. Rincel, M. *et al.* Pharmacological restoration of gut barrier function in stressed neonates partially reverses long-term alterations associated with maternal separation. *Psychopharmacology (Berl)*. **236**, 1583–1596 (2019).
52. Rincel, M. *et al.* Multi-hit early life adversity affects gut microbiota, brain and behavior in a sex-dependent manner. *Brain. Behav. Immun.* 0–1 (2019). doi:10.1016/j.bbi.2019.03.006
53. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, stability and resilience of the human gut microbiota. *Nature* **489**, 220–230 (2012).
54. Lyte, M. & Brown, D. R. Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of *Lactobacillus*: Implications for interkingdom communication within the microbiota-gut-brain axis. *PLoS One* **13**, e0191037 (2018).
55. Zhou, Z. *et al.* Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. *Nat. Struct. Mol. Biol.* **16**, 652–657 (2009).
56. Barouei, J., Moussavi, M. & Hodgson, D. M. Effect of Maternal Probiotic Intervention on HPA Axis, Immunity and Gut Microbiota in a Rat Model of Irritable Bowel Syndrome. *PLoS One* **7**, 1–13 (2012).
57. Zhao, J. *et al.* A comprehensive metabolomics investigation of hippocampus, serum, and feces affected by chronic fluoxetine treatment using the chronic unpredictable mild stress mouse model of depression. *Sci. Rep.* **9**, 7566 (2019).


58. Gill, S. R., Pop, M., Deboy, R. T. & others. Metagenomic analysis of the human distal gut microbiome. *Science* (80-.). **312**, 1355–1359 (2006).
59. Lin, R., Liu, W., Piao, M. & Zhu, H. A review of the relationship between the gut microbiota and amino acid metabolism. *Amino Acids* **49**, 2083–2090 (2017).
60. Neis, E. P. J. G., Dejong, C. H. C. & Rensen, S. S. The role of microbial amino acid metabolism in host metabolism. *Nutrients* **7**, 2930–2946 (2015).
61. Dai, Z.-L., Wu, G. & Zhu, W.-Y. Amino acid metabolism in intestinal bacteria: links between gut ecology and host health. *Front. Biosci. (Landmark Ed.)* **16**, 1768–86 (2011).
62. Kidd, M. *et al.* Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. *Am. J. Physiol. Liver Physiol.* **295**, G260–G272 (2008).
63. Derrien, M. *et al.* Mucin-bacterial interactions in the human oral cavity and digestive tract. *Gut Microbes* **1**, 254–268 (2010).
64. Louis, P. & Flint, H. J. Formation of propionate and butyrate by the human colonic microbiota. *Environ. Microbiol.* **19**, 29–41 (2017).
65. Li, D. *et al.* Microbial Biogeography and Core Microbiota of the Rat Digestive Tract. *Sci. Rep.* **8**, 1–16 (2017).
66. Hiemke C & Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. *Pharmacol. Ther.* **85**, 11–28 (2000).
67. Lemberger, L. *et al.* Fluoxetine: Clinical pharmacology and physiologic disposition. *J. Clin. Psychiatry* (1985).
68. Hillier, S. E. & Olander, E. K. Women's dietary changes before and during pregnancy: A systematic review. *Midwifery* **49**, 19–31 (2017).
69. David, L. A. *et al.* Diet rapidly and reproducibly alters the human gut microbiome. *Nature* **505**, 559–563 (2014).
70. Cusotto, S., Clarke, G., Dinan, T. G. & Cryan, J. F. Psychotropics and the Microbiome: a Chamber of Secrets.... *Psychopharmacology (Berl.)* (2019). doi:10.1007/s00213-019-5185-8
71. Olivier, J. D. A. *et al.* The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. *Front. Cell. Neurosci.* **7**, 73 (2013).
72. Jašarević, E. *et al.* The maternal vaginal microbiome partially mediates the effects of prenatal stress on offspring gut and hypothalamus. *Nat. Neurosci.* (2018). doi:10.1038/s41593-018-0182-5.
73. Pronovost, G. N. & Hsiao, E. Y. Perinatal Interactions between the Microbiome, Immunity, and Neurodevelopment. *Immunity* **50**, 18–36 (2019).
74. Smits, B. M. G. *et al.* Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesis. *Pharmacogenet. Genomics* **16**, 159–169 (2006).
75. Capello, C. F. *et al.* Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk. *J. Pharmacol. Exp. Ther.* **339**, 275–85 (2011).
76. Houwing, D. J. *et al.* Subjecting Dams to Early Life Stress and Perinatal Fluoxetine Treatment Differentially Alters Social Behavior in Young and Adult Rat Offspring. *Front. Neurosci.* **13**, 1–15 (2019).
77. Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the miseq illumina sequencing platform. *Appl. Environ. Microbiol.* **79**, 5112–5120 (2013).
78. Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **7**, 335–336 (2010).
79. Schloss, P. D. *et al.* Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl. Environ. Microbiol.* **75**, 7537–7541 (2009).
80. Liaw, A. & Wiener, M. Classification and Regression by randomForest. *R news* **2**, 18–22 (2002).
81. Langille, M. G. I. *et al.* Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. *Nat. Biotechnol.* **31**, 814–821 (2013).
82. Xia, J., Sinelnikov, I. V., Han, B. & Wishart, D. S. MetaboAnalyst 3.0-making metabolomics more meaningful. *Nucleic Acids Res.* **43**, W251–W257 (2015).
83. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci.* **102**, 15545–15550 (2005).

84. Anderson, M. J. *et al.* A new method for non-parametric multivariate analysis of variance. *Austral Ecol.* **26**, 32–46 (2001).
85. Gloor, G. B. & Reid, G. Compositional analysis: a valid approach to analyze microbiome high-throughput sequencing data. *Can. J. Microbiol.* **62**, 692–703 (2016).


Supplementals





Supplementary Figure 1: The effect of early life stress on the gut microbiome in adult MV female rats. a) Pre-conception alpha diversity. A t-test was used to test whether adult cMV and sMV females differed in terms of fecal microbial Shannon Diversity. **(b)** Pre-conception microbiome composition. A stack plot of the 20 most abundant OTUs was used to compare the fecal microbiome composition of cMV and sMV females. N=18 for cMV; N=14 for sMV.




b











Supplementary Figure 2 (related to Figure 2): The effect of early life stress and fluoxetine on the microbiome during pregnancy and lactation. (a) Random Forests model to determine which OTUs were best able to distinguish between pregnancy and lactation in the cMV-Veh group. The inset figure shows increasing numbers of 97%-identity OTUs on the x-axis plotted against the cross-validation error of the model on the y-axis. It was determined that the optimal model would include the top 28 OTUs, which are shown in the bigger bar graph. From top to bottom, the OTUs are shown in descending order, corresponding to their importance to discriminating between pregnancy and lactation. The length of the bars represents the mean decrease in accuracy of the model if this OTU would be removed from the model. (b) Structure of the microbial communities during pregnancy and lactation. Communities were clustered using PCoA of the weighted UniFrac distance matrix. Each point corresponds to the microbial community of one sample that was collected during pregnancy or lactation. The percentage of variation explained by the PC is indicated on the axes. Colors correspond to group (containing samples from both pregnancy and lactation). (c) Bar graphs showing relative abundance of selected Random Forests-identified OTUs. Two-way ANOVAs with early life stress and FLX were used within pregnancy and lactation to analyze OTU relative abundance. Note: this analysis was performed on centered log-ratio transformed data (see Methods). Only OTUs with a median relative abundance > 0 in at least 1 of the groups are shown here. (d) Correlation matrix of OTUs throughout pregnancy and lactation. Spearman's rank correlations were determined between the 28 Random Forests-identified OTUs. The circles represent the correlation between two given OTUs, with the size of the circle increasing with decreasing p-value of the correlation, and the color of the circle corresponding to the p-value of the correlation (the strength of the correlation). Only significant ($p < 0.05$) correlations are plotted. The OTUs are ordered by hierarchical clustering. $N = 12$ -22 samples/group from pregnancy ($N = 64$ in total), $N = 18$ -33/group from lactation ($N = 96$ in total).


a





b




c










e










Supplementary Figure 3 (related to Figure 3): The effect of early life stress and fluoxetine on metabolite availability during pregnancy and lactation. (a) Random Forests model to determine which predicted KEGG metabolic pathways were best able to distinguish between pregnancy and lactation in the cMV-Veh group. The inset figure shows increasing numbers of KEGG metabolic pathways on the x-axis plotted against the cross-validation error of the model on the y-axis. It was determined that the optimal model would include the top 9 KEGG metabolic pathways. The length of the bars represents the mean decrease in accuracy of the model if this KEGG pathway would be removed from the model. (b) Random Forests model to determine which metabolites were best able to distinguish between pregnancy and lactation in the cMV-Veh group. The smaller figure shows increasing numbers metabolites on the x-axis plotted against the cross-validation error of the model on the y-axis. It was determined that the optimal model would include the top 14 metabolites, which are shown in the bigger bar graph. The length of the bars represents the mean decrease in accuracy of the model if this metabolite would be removed from the model. (c) Bar graphs showing concentrations of Random Forests-identified metabolites. Two-way ANOVAs with early life stress and FLX as factors were used to analyze metabolite concentrations. (d) Bar graphs showing concentrations of the non-Random Forests-

identified metabolites. Analysis was done as described in (c). (e) Metabolite Set Enrichment Analysis of pregnancy vs lactation per group. MSEA was used to identify the metabolic pathways distinguishing pregnancy and lactation based on the metabolomics concentration table for each group. For a: N=22 cMV-Veh samples from pregnancy and N=33 from lactation. For b: N=5 cMV-Veh samples from pregnancy and N=5 from lactation. For c: N=4-5/group from pregnancy and N=4-5/group from lactation (N=36 in total).



Supplementary Figure 4: Alpha- and beta diversity measures in cMV group, revealing PND2 as belonging to neither pregnancy nor lactation. (a) Alpha diversity. Shannon diversity was similar in GD7 and GD14 samples (grouped as pregnancy) and PND7, PND14 and PND21 samples (grouped as lactation), while PND2 alpha diversity falls in between. (b) Beta diversity. Left graph: Weighted UniFrac distances within pregnancy samples are smallest, while differing significantly from PND2 ($p<0.0001$) and from lactation samples ($p<0.0001$). Right graph: Lactation samples are also most similar to themselves, differing significantly from pregnancy ($p<0.0001$) and from PND2 samples ($p<0.0001$). ANOVAs with Tukey's Honest Significant Difference post hoc tests were used for analysis.

Supplementary Table 1: Excel file containing detailed UPLC methods and resulting measured concentrations of amino acids (sheet 1), bile acids (sheet 2) and short-chain fatty acids (sheet 3).

Available at <https://www.tandfonline.com/doi/full/10.1080/19490976.2019.1705728>.